Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
Rhea-AI Summary
Celldex (NASDAQ: CLDX) announced on Nov 10, 2025 the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer.
Ms. Lawver brings 30 years of commercial and P&L leadership, including leadership of $4B annual revenue and 1,900 employees as Chief Commercial Officer at Dexcom, and prior global immunology roles at Johnson & Johnson. She succeeds Richard Wright, who will retire after more than a decade at Celldex. Management cited her experience with major biologic launches and immunology expertise as relevant as Celldex prepares for a potential launch of barzolvolimab and advances its pipeline.
Positive
- 30 years of strategic commercial leadership
- Managed $4B annual revenue and 1,900 employees at Dexcom
- Direct experience launching REMICADE, STELARA, and TREMFYA
Negative
- Transition risk as Richard Wright retires after more than a decade of leadership
News Market Reaction – CLDX
On the day this news was published, CLDX declined 1.00%, reflecting a mild negative market reaction. Argus tracked a peak move of +4.6% during that session. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $17M from the company's valuation, bringing the market cap to $1.64B at that time.
Data tracked by StockTitan Argus on the day of publication.
HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30 years of strategic, commercial launch and operating P&L leadership across the biopharmaceutical, medical device and consumer health technology sectors. Ms. Lawver succeeds Richard Wright, who will retire from Celldex following more than a decade of dedicated leadership and service.
“We are thrilled to welcome Teri to the Celldex leadership team,” said Anthony Marucci, Co-founder, President, and Chief Executive Officer of Celldex. “Teri brings an extraordinary record of success across global biopharmaceutical and medical technology companies. Her deep experience in immunology and inflammation and track record building and scaling commercial organizations will be invaluable as we prepare for the potential launch of barzolvolimab and advance our broader pipeline. I also want to sincerely thank Rick for his exceptional contributions over the past ten years. His leadership and commitment have been instrumental in positioning Celldex for our next phase of growth, and we wish him all the best in his retirement.”
Ms. Lawver brings extensive experience in immunology and inflammation, having overseen multiple first-in-class portfolio advances and blockbuster launches, including pivotal indications for REMICADE® (infliximab), STELARA® (ustekinumab), and TREMFYA® (guselkumab). Prior to joining Celldex, Ms. Lawver was Principal and Owner of Thera Lifescience Advisors, where she was a strategic advisor to CEOs and investors at pioneering life science and health technology companies. Previously, Ms. Lawver was Chief Commercial Officer at Dexcom, Inc. where she was responsible for
Ms. Lawver added, “I am thrilled to join Celldex at such a pivotal time in the company’s evolution. The company’s leadership in advancing mast cell biology and the team’s commitment to transforming outcomes for patients with severe allergic and inflammatory diseases are truly exciting. I look forward to contributing to Celldex’s mission and working alongside this talented team to bring the potential of these important therapies to patients in need.”
About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com.
Forward Looking Statement
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159) and CDX-622, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com
FAQ
Who is Celldex's new Chief Commercial Officer (CLDX) as of Nov 10, 2025?
What commercial experience does Teri Lawver bring to CLDX?
What does Teri Lawver's appointment mean for Celldex's barzolvolimab launch plans?
Who is leaving Celldex's commercial leadership and when?
What prior product launches has Teri Lawver led that are relevant to CLDX?
